奥美沙坦联合前列地尔对糖尿病伴微量白蛋白尿的干预分析  

Intervention analysis of olmesartan and alprostadi on diabetic patients with microalbuminuria

作　　者：严连喜[1] 周玉坤[1] 李康峰[1] 

机构地区：[1]第二军医大学长征医院南京分院肾内科,江苏南京210015

出　　处：《实用临床医药杂志》2014年第16期123-124,127,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察奥美沙坦及奥美沙坦联合前列地尔对糖尿病伴微量蛋白尿的干预。方法选择2012年11月—2013年11月本科室确诊为2型糖尿病40例患者,分为单用奥美沙坦组(A组)、奥美沙坦联合前列地尔组(B组),治疗2周。观察治疗前后2组尿微量白蛋白、肾小球率过滤、血压、高敏C反应蛋白及血凝的变化。结果疗程内,B组较A组对糖尿病伴微量蛋白尿的影响差异有统计学意义;2组对肾小球率过滤、血压、高敏C反应蛋白影响差异也有统计学意义;2组对血凝改变差异无统计学意义。结论奥美沙坦联合前列地尔短期内降低尿微量白蛋白、肾小球率过滤、血压、高敏C反应蛋白,与其抑制肾素-血管紧张素系统、抗肾脏局部高凝及抑制微炎症状态相关。Objective To observe the impact of olmesartan and alprostadi on diabetic patients with microalbuminuria. Methods 40 patients were divided into group A given olmesartan and B group given olmesartan and alprostadil. The two groups were treated for 2 weeks. The changes of microalbuminuria 、glomerular filtration rate,blood pressure,high-sensitivity C-reactive protein and blood clotting were observed. Results During the treament,there was statistically significant in the effect of microalbuminuria in group B than that in group A; There were significant difference in two groups of glomerular filtration rate,blood pressure,high-sensitivity C-reactive protein,and there was no significant difference in two groups of clotting change. Conclusion In group B,reduced microalbuminuria,glomerular filtration rate,blood pressure,high-sensitivity C-reactive protein was related with inhibition of the renin-angiotensin,and related to anti-kidney local hypercoagulable and micro-inflammatory state.

关 键 词：糖尿病 微量白蛋白尿 奥美沙坦 前列地尔 

分 类 号：R587.1[医药卫生—内分泌]